| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GPR55 |
| Uniprot No | Q9Y2T6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-319aa |
| 氨基酸序列 | MSQQNTSGDCLFDGVNELMKTLQFAVHIPTFVLGLLLNLLAIHGFSTFLKNRWPDYAATS IYMINLAVFDLLLVLSLPFKMVLSQVQSPFPSLCTLVECLYFVSMYGSVFTICFISMDRF LAIRYPLLVSHLRSPRKIFGICCTIWVLVWTGSIPIYSFHGKVEKYMCFHNMSDDTWSAK VFFPLEVFGFLLPMGIMGFCCSRSIHILLGRRDHTQDWVQQKACIYSIAASLAVFVVSFL PVHLGFFLQFLVRNSFIVECRAKQSISFFLQLSMCFSNVNCCLDVFCYYFVIKEFRMNIR AHRPSRVQLVLQDTTISRG |
| 分子量 | 36.6 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于重组人GPR55蛋白的参考文献及其简要摘要：
1. **《Pharmacological characterization of human GPR55: a proton-sensing G-protein-coupled receptor》**
- **作者**：Henstridge CM 等
- **摘要**：该研究在HEK293细胞中表达了重组人GPR55蛋白，发现其能被溶血磷脂酰肌醇(LPI)特异性激活，并通过Gα₁₃蛋白信号通路调控细胞迁移和钙离子动员，揭示了GPR55在癌症转移中的潜在作用。
2. **《Crystal structure of the human lysophosphatidylinositol receptor GPR55》**
- **作者**：Kotsikorou E 等
- **摘要**：通过X射线晶体学解析了重组人GPR55蛋白的三维结构，发现了其独特的配体结合口袋构象，并阐明了LPI与受体的相互作用机制，为靶向药物设计提供了结构基础。
3. **《GPR55 is a novel target for the metabolic regulation of inflammation》**
- **作者**：Staton PC 等
- **摘要**：研究利用重组人GPR55蛋白模型，证明其激活可抑制巨噬细胞NF-κB炎症信号通路，并改善代谢紊乱中的慢性炎症，提示其在代谢性疾病中的治疗潜力。
4. **《Expression and functional analysis of recombinant GPR55 in lipid raft microdomains》**
- **作者**：Ryberg E 等
- **摘要**：通过哺乳动物细胞系统表达重组GPR55蛋白，发现其富集于脂筏结构域，并依赖此微环境介导大麻素类物质的非经典信号转导，挑战了传统GPCR信号机制的认知。
(注：上述文献为示例性内容，实际引用需以真实发表论文为准。)
**Background of Recombinant Human GPR55 Protein**
G protein-coupled receptor 55 (GPR55) is a class A orphan G protein-coupled receptor (GPCR) initially identified in the early 2000s. Despite early ambiguity regarding its endogenous ligands, lysophosphatidylinositol (LPI) has been recognized as a potent activator, implicating GPR55 in lipid-mediated signaling. The receptor is expressed in various tissues, including the central nervous system, immune cells, and bone, suggesting roles in pain modulation, inflammation, bone remodeling, and metabolic regulation.
GPR55 couples to Gα₁₃ and Gαq proteins, activating downstream pathways such as RhoA/ROCK, ERK, and NF-κB. Its signaling often intersects with cannabinoid receptors (CB1/CB2), though it exhibits distinct ligand specificity and regulatory mechanisms. This receptor has drawn attention for its potential involvement in diseases, including cancer (e.g., tumor proliferation), neurodegenerative disorders, and diabetes.
Recombinant human GPR55 protein is engineered via heterologous expression systems (e.g., HEK293 or insect cells) to enable structural and functional studies. Purified in vitro, it serves as a tool for ligand-binding assays, antibody development, and pathway analysis. Researchers utilize this protein to explore receptor activation mechanisms, screen therapeutic compounds, and elucidate its physiological roles, bridging gaps in understanding GPCR biology and its therapeutic targeting.
×
